MarketLens

What is the latest on Capricor Therapeutics' Deramiocel and its FDA journey

6 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

What is Seaport Therapeutics and Why is its IPO Significant

5 months ago

What Does the FDA's NDA Acceptance Mean for Mineralys Therapeutics

4 months ago

Is Veradigm (MDRX) Poised for a Comeback After Its Tumultuous Journey

4 months ago

What Does Ultragenyx's Latest FDA Clearance Mean for Investors

5 months ago

Hagens Berman Alerts Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to FDA Review Extension for Deramiocel Amid Ongoing Securities Class Action and September 28 Lead Plaintiff Deadline

Hagens Berman alerted Capricor Therapeutics investors to a September 28, 2026 lead plaintiff deadline in an ongoing securities class action, tied to an FDA review extension for Deramiocel. The notice ...

CAPR

Stock News•4 weeks ago

Capricor Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Capricor Therapeutics reported ~$238M in cash as of June 30, 2026, while its deramiocel BLA remains under FDA review. HOPE-3 Phase 3 results published in The Lancet showed the primary upper limb endpo...

CAPR

Stock News•1 months ago

FDA panel votes against Capricor's Duchenne heart disease therapy

Capricor Therapeutics' deramiocel faced an FDA panel vote against its benefits for Duchenne cardiomyopathy, a setback for the rare-disease cell therapy.

CAPR